ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Pooled it
- Proteomic Analysis of Plasma Reveals Fat Mass Influences Cancer-Related Pathways in Healthy Humans Fed Controlled Diets Differing in Glycemic Load.Cancer prevention research (Philadelphia, Pa.) · 2019Trial
- Exploratory plasma proteomic analysis in a randomized crossover trial of aspirin among healthy men and women.PloS one · 2017Trial
- Missing value imputation on gene expression data using bee-based algorithm to improve classification performance.PloS one · 2024Article
- Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment.Cancers · 2023Article
- Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.International journal of cancer · 2023Article
- Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer.Science translational medicine · 2023Article
- In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for PersonalizedInternational journal of molecular sciences · 2022Article
- Advances in Multiplexed Paper-Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments.Advanced materials technologies · 2021Article
- Modeling pancreatic cancer in mice for experimental therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer-A Comprehensive Review.Cancers · 2021Review
- An efficient ensemble method for missing value imputation in microarray gene expression data.BMC bioinformatics · 2021Article
- Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour.EBioMedicine · 2020Article
- Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.American journal of respiratory and critical care medicine · 2019Article
- A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.Journal of gastroenterology and hepatology · 2019Review
- Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.World journal of gastroenterology · 2018Review
- Article
- Article
- Current applications of antibody microarrays.Clinical proteomics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposePancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States, and its incidence is on the rise. Advanced disease is nearly uniformly lethal, emphasizing the need to identify PDA at its earliest stages. To discover early biomarkers of PDA, we evaluated the circulating proteome in murine preinvasive and invasive plasma samples and human prediagnostic and diagnostic samples. EXPERIMENTAL
designUsing a customized antibody microarray platform containing >4,000 features, we interrogated plasma samples spanning preinvasive and invasive disease from a highly faithful mouse model of PDA. In parallel, we mined prediagnostic plasma from women in the Women's Health Initiative (WHI) who would later succumb to PDA together with matched, cancer-free control samples. Samples collected after an establishing diagnosis of PDA were also interrogated to further validate markers.
resultsWe identified ERBB2 and TNC in our cross-species analyses, and multiple antibodies identified ESR1 in prediagnostic plasma from people that succumb to PDA. This 3-marker panel had an AUC of 0.86 (95% confidence interval [CI], 0.76-0.96) for the diagnostic cohort that increased to 0.97 (95% CI, 0.92-1.0) with CA19-9 included. The 3-marker panel also had an AUC of 0.68 (95% CI, 0.58-0.77) for the prediagnostic cohort.
conclusionsWe identified potential disease detection markers in plasma up to 4 years before death from PDA with superior performance to CA19-9. These markers might be especially useful in high-risk cohorts to diagnose early, resectable disease, particularly in patients that do not produce CA19-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.